HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Korro Bio (NASDAQ:KRRO) with a Buy and maintains $15 price target.
Stocks · News reference
Korro Bio Submits To Australian Alfred Health Human Ethics Committee To Start Phase 1/2 Clinical Study Of KRRO-121 To Treat Hyperammonemia In Patients With Urea Cycle Disorders
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Korro Bio Doses First First Group Of Patients In Its Phase 1/2 Clinical Study Of KRRO-121 To Treat Hyperammonemia In Patients With Urea Cycle Disorders
Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging its oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly
8-K filing — Korro Bio, Inc. (KRRO)
Filed: 2026-10-05 AccNo: 0001193125-26-414118 Size: 232 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits